Aims Empagliflozin, a clinically used oral antidiabetic drug that inhibits the sodiumヾependent glucose co‐transporter 2, has recently been evaluated for its cardiovascular safety. Surprisingly, empagliflozin reduced mortality and hospitalization for heart failure (HF) compared to placebo. However, the ...
Heart failure accounts for more than one million hospitalizations a year in the U.S. Ridgefield, Conn. and Indianapolis, August 18, 2021– Jardiance® (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascu...
RESULTS: From 90 days from the start of closeout to the end of double-blind treatment, the annualized risk of cardiovascular death or hospitalization for heart failure was lower in empagliflozin-treated patients than in placebo-...
by Elana Gotkine For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a study published online April 6 inCirculationto coincide with the annual meeting of the American College of Cardiology, held from A...
“Empagliflozin reduced the risk of CV death and hospitalisation for heart failure by 25%, reduced total hospitalisations for heart failure by 30%, and reduced the composite of chronic dialysis, transplant and renal death by 50%,” said Dr. Zannad. “All 3 benefits were seen consistently in...
Empagliflozin (Jardiance®), a sodium-glucose cotransporter 2 inhibitor (SGLT2i) initially developed to treat type 2 diabetes mellitus (T2DM), has also been approved in the EU and USA for the treatment of all adults with symptomatic chronic heart failure (CHF), regardless of their left ventri...
The base case rate of hospitalization for heart failure is shown as a vertical line. Duration of disutility may also be interpreted as severity of quality-of-life impairment (eg, 2 months of disutility equivalent to 1 month of disutility twice as severe as the base case estimate). CV ...
Subsequent to the report of results from the EMPEROR-Reduced trial nearly a year ago, heart failure expertsdeclaredthat treatment with an agent from the SGLT2 inhibitor class had become a "new pillar of foundational therapy for HFrEF," and they urged rapid initiation of an SGLT2 inhibitor (alo...
The heart failure (HF) epidemic is one of the challenges that has been faced by the healthcare system worldwide for almost 25 years. With an ageing world population and a fast-paced lifestyle that promotes the development of cardiovascular disease, the number of people suffering from heart fai...
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unk...